5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed chimeric antigen receptor T cells
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Olszewska, M.; Taylor, C.; Wasielewska, T.; Bartido, S.; Poon, S.; Scher, H. I.; more...
    Molecular Therapy (2012)

    Fulltext@MSK | Save
  • Relationship between Karnofsky Performance Status (KPS) and tumor response: Analysis of the RECORD-1 phase 3 trial of everolimus in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Porta, C.; Escudier, B.; Hutson, T. E.; Figlin, R.; Calvo, E.; Grünwald, V.; Osanto, S.; Ravaud, A.; Panneerselvam, A.; Knox, J. J.; more...
    BJU International (2012)

    Fulltext@MSK | Save
  • A multicenter, open-label, randomized phase 3 trial comparing the safety and efficacy of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies
    Meeting Abstract

    Motzer, R.; Sternberg, C. N.; Vogelzang, N.; Urbanowitz, G.; Cai, C.; Kay, A.; Escudier, B.
    BJU International (2012)

    Fulltext@MSK | Save
  • Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R. J.; Escudier, B.; Bukowski, R.; Rini, B. I.; Hutson, T. E.; Barrios, C. H.; Lin, X.; Fly, K.; Matczak, E.; Gore, M. E.
    BJU International (2012)

    Fulltext@MSK | Save
  • A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Hutson, T. E.; Bukowski, R.; Rini, B. I.; Gore, M. E.; Larkin, J. M.; Figlin, R. A.; Barrios, C. H.; Escudier, B.; Lin, X.; Fly, K.; more...
    BJU International (2012)

    Fulltext@MSK | Save
  • Subgroup analysis of the phase 3 RECORD-1 trial of everolimus in patients with metastatic renal cell carcinoma: 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies
    Meeting Abstract

    Figlin, R. A.; Motzer, R.; Hutson, T. E.; Oudard, S.; Porta, C.; Grünwald, V.; Ravaud, A.; Panneerselvam, A.; Calvo, E.
    BJU International (2012)

    Fulltext@MSK | Save
  • Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Escudier, B.; Rini, B. I.; Hutson, T. E.; Gore, M.; Oudard, S.; Tarazi, J.; Rosbrook, B.; Williams, J. A.; Kim, S.; Motzer, R. J.
    European Urology, Supplements (2012)

    Fulltext@MSK | Save
  • Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer
    Journal Article

    Saltz, L.; Badarinath, S.; Dakhil, S.; Bienvenu, B.; Harker, W. G.; Birchfield, G.; Tokaz, L. K.; Barrera, D.; Conkling, P. R.; O'Rourke, M. A.; more...
    Clinical Colorectal Cancer (2012)

    Fulltext@MSK | Save
  • Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
    Journal Article

    Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, M. D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
    British Journal of Cancer (2012)

    Fulltext@MSK | Save
  • Testicular cancer
    Journal Article

    Motzer, R. J.; Agarwal, N.; Beard, C.; Bhayani, S.; Bolger, G. B.; Buyyounouski, M. K.; Carducci, M. A.; Chang, S. S.; Choueiri, T. K.; Gupta, S.; more...
    Journal of the National Comprehensive Cancer Network (2012)

    Fulltext@MSK | Save